nodes	percent_of_prediction	percent_of_DWPC	metapath
Iloperidone—CYP2E1—Fingolimod—multiple sclerosis	0.117	0.236	CbGbCtD
Iloperidone—CYP2D6—Fingolimod—multiple sclerosis	0.0556	0.113	CbGbCtD
Iloperidone—CYP2E1—Mitoxantrone—multiple sclerosis	0.0548	0.111	CbGbCtD
Iloperidone—CYP3A4—Fingolimod—multiple sclerosis	0.0353	0.0716	CbGbCtD
Iloperidone—HTR1D—trigeminal nucleus—multiple sclerosis	0.0326	0.189	CbGeAlD
Iloperidone—CYP3A7—Dexamethasone—multiple sclerosis	0.0294	0.0596	CbGbCtD
Iloperidone—CYP3A7-CYP3A51P—Dexamethasone—multiple sclerosis	0.0294	0.0596	CbGbCtD
Iloperidone—CYP2E1—Dexamethasone—multiple sclerosis	0.0284	0.0576	CbGbCtD
Iloperidone—CYP3A4—Methylprednisolone—multiple sclerosis	0.0228	0.0461	CbGbCtD
Iloperidone—CYP3A5—Dexamethasone—multiple sclerosis	0.0221	0.0447	CbGbCtD
Iloperidone—HTR1D—meninx—multiple sclerosis	0.0216	0.126	CbGeAlD
Iloperidone—CYP3A4—Triamcinolone—multiple sclerosis	0.0173	0.035	CbGbCtD
Iloperidone—CYP3A4—Mitoxantrone—multiple sclerosis	0.0166	0.0336	CbGbCtD
Iloperidone—HTR2A—trigeminal nucleus—multiple sclerosis	0.0162	0.094	CbGeAlD
Iloperidone—CYP3A4—Betamethasone—multiple sclerosis	0.0148	0.03	CbGbCtD
Iloperidone—CYP3A4—Prednisolone—multiple sclerosis	0.0146	0.0296	CbGbCtD
Iloperidone—CYP3A4—Prednisone—multiple sclerosis	0.0138	0.0279	CbGbCtD
Iloperidone—CYP2D6—Dexamethasone—multiple sclerosis	0.0135	0.0274	CbGbCtD
Iloperidone—CYP3A4—Dexamethasone—multiple sclerosis	0.00861	0.0174	CbGbCtD
Iloperidone—HTR1D—trigeminal nerve—multiple sclerosis	0.00856	0.0497	CbGeAlD
Iloperidone—HTR7—pons—multiple sclerosis	0.0048	0.0279	CbGeAlD
Iloperidone—HTR2A—trigeminal nerve—multiple sclerosis	0.00425	0.0247	CbGeAlD
Iloperidone—DRD1—nerve—multiple sclerosis	0.00398	0.0231	CbGeAlD
Iloperidone—HTR7—peripheral nervous system—multiple sclerosis	0.00319	0.0186	CbGeAlD
Iloperidone—HTR2A—pons—multiple sclerosis	0.00299	0.0174	CbGeAlD
Iloperidone—HTR7—nerve—multiple sclerosis	0.00249	0.0145	CbGeAlD
Iloperidone—DRD2—nerve—multiple sclerosis	0.00235	0.0137	CbGeAlD
Iloperidone—ADRA2A—peripheral nervous system—multiple sclerosis	0.00234	0.0136	CbGeAlD
Iloperidone—HTR2A—pineal body—multiple sclerosis	0.00214	0.0124	CbGeAlD
Iloperidone—HTR2A—peripheral nervous system—multiple sclerosis	0.00199	0.0116	CbGeAlD
Iloperidone—DRD1—brainstem—multiple sclerosis	0.00171	0.00994	CbGeAlD
Iloperidone—HTR2A—nerve—multiple sclerosis	0.00155	0.00902	CbGeAlD
Iloperidone—DRD4—brain—multiple sclerosis	0.00136	0.00791	CbGeAlD
Iloperidone—HTR1D—brainstem—multiple sclerosis	0.00134	0.0078	CbGeAlD
Iloperidone—HTR2C—brainstem—multiple sclerosis	0.00133	0.00772	CbGeAlD
Iloperidone—DRD3—nervous system—multiple sclerosis	0.00125	0.00727	CbGeAlD
Iloperidone—DRD3—central nervous system—multiple sclerosis	0.0012	0.007	CbGeAlD
Iloperidone—HTR6—nervous system—multiple sclerosis	0.0012	0.007	CbGeAlD
Iloperidone—HTR6—central nervous system—multiple sclerosis	0.00116	0.00674	CbGeAlD
Iloperidone—HTR1A—brainstem—multiple sclerosis	0.00112	0.0065	CbGeAlD
Iloperidone—DRD1—midbrain—multiple sclerosis	0.00109	0.00633	CbGeAlD
Iloperidone—HTR7—brainstem—multiple sclerosis	0.00107	0.00621	CbGeAlD
Iloperidone—ADRA1A—brainstem—multiple sclerosis	0.00103	0.00599	CbGeAlD
Iloperidone—DRD2—brainstem—multiple sclerosis	0.00101	0.00587	CbGeAlD
Iloperidone—DRD2—retina—multiple sclerosis	0.000975	0.00566	CbGeAlD
Iloperidone—DRD3—brain—multiple sclerosis	0.000956	0.00556	CbGeAlD
Iloperidone—HTR2C—medulla oblongata—multiple sclerosis	0.000926	0.00538	CbGeAlD
Iloperidone—HTR6—brain—multiple sclerosis	0.000921	0.00535	CbGeAlD
Iloperidone—DRD1—nervous system—multiple sclerosis	0.000896	0.00521	CbGeAlD
Iloperidone—SIGMAR1—medulla oblongata—multiple sclerosis	0.000872	0.00507	CbGeAlD
Iloperidone—DRD1—central nervous system—multiple sclerosis	0.000863	0.00501	CbGeAlD
Iloperidone—HTR1D—midbrain—multiple sclerosis	0.000855	0.00497	CbGeAlD
Iloperidone—HTR2C—midbrain—multiple sclerosis	0.000847	0.00492	CbGeAlD
Iloperidone—HTR2C—spinal cord—multiple sclerosis	0.000826	0.0048	CbGeAlD
Iloperidone—SIGMAR1—midbrain—multiple sclerosis	0.000797	0.00463	CbGeAlD
Iloperidone—SIGMAR1—spinal cord—multiple sclerosis	0.000778	0.00452	CbGeAlD
Iloperidone—HTR7—medulla oblongata—multiple sclerosis	0.000745	0.00433	CbGeAlD
Iloperidone—HTR1A—midbrain—multiple sclerosis	0.000713	0.00414	CbGeAlD
Iloperidone—HTR1D—nervous system—multiple sclerosis	0.000703	0.00408	CbGeAlD
Iloperidone—HTR2C—nervous system—multiple sclerosis	0.000696	0.00404	CbGeAlD
Iloperidone—HTR1A—spinal cord—multiple sclerosis	0.000695	0.00404	CbGeAlD
Iloperidone—ADRA2C—medulla oblongata—multiple sclerosis	0.000685	0.00398	CbGeAlD
Iloperidone—DRD1—brain—multiple sclerosis	0.000685	0.00398	CbGeAlD
Iloperidone—HTR7—midbrain—multiple sclerosis	0.000681	0.00396	CbGeAlD
Iloperidone—HTR1D—central nervous system—multiple sclerosis	0.000677	0.00393	CbGeAlD
Iloperidone—HTR2C—central nervous system—multiple sclerosis	0.00067	0.00389	CbGeAlD
Iloperidone—HTR2A—brainstem—multiple sclerosis	0.000666	0.00387	CbGeAlD
Iloperidone—HTR7—spinal cord—multiple sclerosis	0.000664	0.00386	CbGeAlD
Iloperidone—DRD2—midbrain—multiple sclerosis	0.000644	0.00374	CbGeAlD
Iloperidone—HTR2A—retina—multiple sclerosis	0.000643	0.00374	CbGeAlD
Iloperidone—ADRA2C—midbrain—multiple sclerosis	0.000626	0.00364	CbGeAlD
Iloperidone—SIGMAR1—cerebellum—multiple sclerosis	0.000617	0.00358	CbGeAlD
Iloperidone—ADRA2C—spinal cord—multiple sclerosis	0.000611	0.00355	CbGeAlD
Iloperidone—CYP2D6—brainstem—multiple sclerosis	0.000607	0.00353	CbGeAlD
Iloperidone—HTR1A—nervous system—multiple sclerosis	0.000586	0.0034	CbGeAlD
Iloperidone—HTR1A—central nervous system—multiple sclerosis	0.000564	0.00328	CbGeAlD
Iloperidone—HTR7—nervous system—multiple sclerosis	0.00056	0.00325	CbGeAlD
Iloperidone—HTR1A—cerebellum—multiple sclerosis	0.000551	0.0032	CbGeAlD
Iloperidone—ADRA2A—medulla oblongata—multiple sclerosis	0.000547	0.00318	CbGeAlD
Iloperidone—ADRA1A—nervous system—multiple sclerosis	0.00054	0.00314	CbGeAlD
Iloperidone—HTR7—central nervous system—multiple sclerosis	0.000539	0.00313	CbGeAlD
Iloperidone—HTR1D—brain—multiple sclerosis	0.000537	0.00312	CbGeAlD
Iloperidone—CYP2E1—medulla oblongata—multiple sclerosis	0.000535	0.00311	CbGeAlD
Iloperidone—HTR2C—brain—multiple sclerosis	0.000532	0.00309	CbGeAlD
Iloperidone—DRD2—nervous system—multiple sclerosis	0.000529	0.00308	CbGeAlD
Iloperidone—HTR7—cerebellum—multiple sclerosis	0.000527	0.00306	CbGeAlD
Iloperidone—ADRA1A—central nervous system—multiple sclerosis	0.00052	0.00302	CbGeAlD
Iloperidone—ADRA2C—nervous system—multiple sclerosis	0.000515	0.00299	CbGeAlD
Iloperidone—DRD2—central nervous system—multiple sclerosis	0.00051	0.00296	CbGeAlD
Iloperidone—ADRA1A—cerebellum—multiple sclerosis	0.000508	0.00295	CbGeAlD
Iloperidone—SIGMAR1—brain—multiple sclerosis	0.000501	0.00291	CbGeAlD
Iloperidone—ADRA2A—midbrain—multiple sclerosis	0.000499	0.0029	CbGeAlD
Iloperidone—DRD2—cerebellum—multiple sclerosis	0.000498	0.00289	CbGeAlD
Iloperidone—ADRA2C—central nervous system—multiple sclerosis	0.000495	0.00288	CbGeAlD
Iloperidone—Somnolence—Cladribine—multiple sclerosis	0.000491	0.00252	CcSEcCtD
Iloperidone—ADRA2A—spinal cord—multiple sclerosis	0.000487	0.00283	CbGeAlD
Iloperidone—ADRA2C—cerebellum—multiple sclerosis	0.000484	0.00281	CbGeAlD
Iloperidone—Asthma—Triamcinolone—multiple sclerosis	0.000482	0.00247	CcSEcCtD
Iloperidone—Mood swings—Betamethasone—multiple sclerosis	0.000479	0.00245	CcSEcCtD
Iloperidone—Mood swings—Dexamethasone—multiple sclerosis	0.000479	0.00245	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Cladribine—multiple sclerosis	0.000477	0.00244	CcSEcCtD
Iloperidone—Weight increased—Prednisolone—multiple sclerosis	0.000477	0.00244	CcSEcCtD
Iloperidone—CYP2E1—spinal cord—multiple sclerosis	0.000477	0.00277	CbGeAlD
Iloperidone—Fatigue—Cladribine—multiple sclerosis	0.000476	0.00244	CcSEcCtD
Iloperidone—Increased appetite—Prednisone—multiple sclerosis	0.000469	0.0024	CcSEcCtD
Iloperidone—Amnesia—Prednisone—multiple sclerosis	0.000469	0.0024	CcSEcCtD
Iloperidone—Arthralgia—Azathioprine—multiple sclerosis	0.000469	0.0024	CcSEcCtD
Iloperidone—Myalgia—Azathioprine—multiple sclerosis	0.000469	0.0024	CcSEcCtD
Iloperidone—HTR2A—medulla oblongata—multiple sclerosis	0.000465	0.0027	CbGeAlD
Iloperidone—Hypokalaemia—Dexamethasone—multiple sclerosis	0.00046	0.00236	CcSEcCtD
Iloperidone—Hypokalaemia—Betamethasone—multiple sclerosis	0.00046	0.00236	CcSEcCtD
Iloperidone—Mouth ulceration—Methotrexate—multiple sclerosis	0.000458	0.00235	CcSEcCtD
Iloperidone—Arrhythmia—Mitoxantrone—multiple sclerosis	0.000457	0.00234	CcSEcCtD
Iloperidone—Feeling abnormal—Cladribine—multiple sclerosis	0.000455	0.00233	CcSEcCtD
Iloperidone—Conjunctivitis—Prednisolone—multiple sclerosis	0.000454	0.00233	CcSEcCtD
Iloperidone—Gynaecomastia—Methotrexate—multiple sclerosis	0.000454	0.00232	CcSEcCtD
Iloperidone—Cardiac failure—Prednisone—multiple sclerosis	0.000451	0.00231	CcSEcCtD
Iloperidone—Lethargy—Prednisone—multiple sclerosis	0.000449	0.0023	CcSEcCtD
Iloperidone—HTR1A—brain—multiple sclerosis	0.000448	0.0026	CbGeAlD
Iloperidone—Upper respiratory tract infection—Triamcinolone—multiple sclerosis	0.000448	0.00229	CcSEcCtD
Iloperidone—Infection—Azathioprine—multiple sclerosis	0.000446	0.00229	CcSEcCtD
Iloperidone—Weight increased—Triamcinolone—multiple sclerosis	0.000438	0.00225	CcSEcCtD
Iloperidone—Weight increased—Methylprednisolone—multiple sclerosis	0.000437	0.00224	CcSEcCtD
Iloperidone—Body temperature increased—Cladribine—multiple sclerosis	0.000437	0.00224	CcSEcCtD
Iloperidone—Affect lability—Prednisone—multiple sclerosis	0.000434	0.00222	CcSEcCtD
Iloperidone—Psychotic disorder—Prednisone—multiple sclerosis	0.00043	0.0022	CcSEcCtD
Iloperidone—HTR7—brain—multiple sclerosis	0.000428	0.00249	CbGeAlD
Iloperidone—HTR2A—midbrain—multiple sclerosis	0.000425	0.00247	CbGeAlD
Iloperidone—Hypotension—Azathioprine—multiple sclerosis	0.00042	0.00215	CcSEcCtD
Iloperidone—Vision blurred—Mitoxantrone—multiple sclerosis	0.000419	0.00215	CcSEcCtD
Iloperidone—HRH1—nervous system—multiple sclerosis	0.000418	0.00243	CbGeAlD
Iloperidone—Conjunctivitis—Triamcinolone—multiple sclerosis	0.000418	0.00214	CcSEcCtD
Iloperidone—Mood swings—Prednisone—multiple sclerosis	0.000417	0.00214	CcSEcCtD
Iloperidone—HTR2A—spinal cord—multiple sclerosis	0.000414	0.00241	CbGeAlD
Iloperidone—ADRA1A—brain—multiple sclerosis	0.000413	0.0024	CbGeAlD
Iloperidone—Anaemia—Mitoxantrone—multiple sclerosis	0.000411	0.00211	CcSEcCtD
Iloperidone—ADRA2A—nervous system—multiple sclerosis	0.000411	0.00239	CbGeAlD
Iloperidone—Musculoskeletal discomfort—Azathioprine—multiple sclerosis	0.000409	0.0021	CcSEcCtD
Iloperidone—Epistaxis—Triamcinolone—multiple sclerosis	0.000405	0.00208	CcSEcCtD
Iloperidone—DRD2—brain—multiple sclerosis	0.000405	0.00235	CbGeAlD
Iloperidone—HRH1—central nervous system—multiple sclerosis	0.000402	0.00234	CbGeAlD
Iloperidone—CYP2E1—nervous system—multiple sclerosis	0.000402	0.00233	CbGeAlD
Iloperidone—Hypokalaemia—Prednisone—multiple sclerosis	0.000401	0.00205	CcSEcCtD
Iloperidone—Renal failure acute—Methotrexate—multiple sclerosis	0.000399	0.00204	CcSEcCtD
Iloperidone—Leukopenia—Mitoxantrone—multiple sclerosis	0.000398	0.00204	CcSEcCtD
Iloperidone—Weight increased—Dexamethasone—multiple sclerosis	0.000398	0.00204	CcSEcCtD
Iloperidone—Weight increased—Betamethasone—multiple sclerosis	0.000398	0.00204	CcSEcCtD
Iloperidone—Asthenia—Cladribine—multiple sclerosis	0.000396	0.00203	CcSEcCtD
Iloperidone—Weight decreased—Dexamethasone—multiple sclerosis	0.000395	0.00203	CcSEcCtD
Iloperidone—Weight decreased—Betamethasone—multiple sclerosis	0.000395	0.00203	CcSEcCtD
Iloperidone—ADRA2A—central nervous system—multiple sclerosis	0.000395	0.0023	CbGeAlD
Iloperidone—ADRA2C—brain—multiple sclerosis	0.000393	0.00229	CbGeAlD
Iloperidone—Gastrointestinal disorder—Azathioprine—multiple sclerosis	0.000388	0.00199	CcSEcCtD
Iloperidone—CYP2E1—central nervous system—multiple sclerosis	0.000387	0.00225	CbGeAlD
Iloperidone—ADRA2A—cerebellum—multiple sclerosis	0.000386	0.00225	CbGeAlD
Iloperidone—Conjunctivitis—Betamethasone—multiple sclerosis	0.000379	0.00194	CcSEcCtD
Iloperidone—Conjunctivitis—Dexamethasone—multiple sclerosis	0.000379	0.00194	CcSEcCtD
Iloperidone—Arthralgia—Mitoxantrone—multiple sclerosis	0.000379	0.00194	CcSEcCtD
Iloperidone—Myalgia—Mitoxantrone—multiple sclerosis	0.000379	0.00194	CcSEcCtD
Iloperidone—Connective tissue disorder—Methylprednisolone—multiple sclerosis	0.000378	0.00194	CcSEcCtD
Iloperidone—CYP2E1—cerebellum—multiple sclerosis	0.000378	0.0022	CbGeAlD
Iloperidone—Diarrhoea—Cladribine—multiple sclerosis	0.000378	0.00194	CcSEcCtD
Iloperidone—Lethargy—Methotrexate—multiple sclerosis	0.000376	0.00192	CcSEcCtD
Iloperidone—Arrhythmia—Prednisolone—multiple sclerosis	0.000375	0.00192	CcSEcCtD
Iloperidone—Feeling abnormal—Azathioprine—multiple sclerosis	0.00037	0.0019	CcSEcCtD
Iloperidone—Confusional state—Mitoxantrone—multiple sclerosis	0.000366	0.00188	CcSEcCtD
Iloperidone—Dizziness—Cladribine—multiple sclerosis	0.000365	0.00187	CcSEcCtD
Iloperidone—Oedema—Mitoxantrone—multiple sclerosis	0.000363	0.00186	CcSEcCtD
Iloperidone—Infection—Mitoxantrone—multiple sclerosis	0.000361	0.00185	CcSEcCtD
Iloperidone—Eye disorder—Methylprednisolone—multiple sclerosis	0.00036	0.00184	CcSEcCtD
Iloperidone—Cardiac disorder—Methylprednisolone—multiple sclerosis	0.000357	0.00183	CcSEcCtD
Iloperidone—Body temperature increased—Azathioprine—multiple sclerosis	0.000355	0.00182	CcSEcCtD
Iloperidone—Tachycardia—Mitoxantrone—multiple sclerosis	0.000354	0.00182	CcSEcCtD
Iloperidone—Erectile dysfunction—Prednisone—multiple sclerosis	0.000351	0.0018	CcSEcCtD
Iloperidone—HTR2A—nervous system—multiple sclerosis	0.000349	0.00203	CbGeAlD
Iloperidone—Angiopathy—Methylprednisolone—multiple sclerosis	0.000349	0.00179	CcSEcCtD
Iloperidone—Mood swings—Methotrexate—multiple sclerosis	0.000349	0.00179	CcSEcCtD
Iloperidone—Rash—Cladribine—multiple sclerosis	0.000348	0.00178	CcSEcCtD
Iloperidone—Dermatitis—Cladribine—multiple sclerosis	0.000348	0.00178	CcSEcCtD
Iloperidone—Mediastinal disorder—Methylprednisolone—multiple sclerosis	0.000347	0.00178	CcSEcCtD
Iloperidone—Weight increased—Prednisone—multiple sclerosis	0.000346	0.00177	CcSEcCtD
Iloperidone—Arrhythmia—Triamcinolone—multiple sclerosis	0.000344	0.00176	CcSEcCtD
Iloperidone—Weight decreased—Prednisone—multiple sclerosis	0.000344	0.00176	CcSEcCtD
Iloperidone—Vision blurred—Prednisolone—multiple sclerosis	0.000344	0.00176	CcSEcCtD
Iloperidone—Arrhythmia—Methylprednisolone—multiple sclerosis	0.000344	0.00176	CcSEcCtD
Iloperidone—Hypotension—Mitoxantrone—multiple sclerosis	0.000339	0.00174	CcSEcCtD
Iloperidone—Mental disorder—Methylprednisolone—multiple sclerosis	0.000337	0.00173	CcSEcCtD
Iloperidone—HTR2A—central nervous system—multiple sclerosis	0.000336	0.00195	CbGeAlD
Iloperidone—Malnutrition—Methylprednisolone—multiple sclerosis	0.000335	0.00172	CcSEcCtD
Iloperidone—Breast disorder—Methotrexate—multiple sclerosis	0.000333	0.0017	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Mitoxantrone—multiple sclerosis	0.000331	0.00169	CcSEcCtD
Iloperidone—HTR2A—cerebellum—multiple sclerosis	0.000329	0.00191	CbGeAlD
Iloperidone—Nausea—Cladribine—multiple sclerosis	0.000328	0.00168	CcSEcCtD
Iloperidone—Vertigo—Prednisolone—multiple sclerosis	0.000328	0.00168	CcSEcCtD
Iloperidone—Eye disorder—Betamethasone—multiple sclerosis	0.000327	0.00168	CcSEcCtD
Iloperidone—Eye disorder—Dexamethasone—multiple sclerosis	0.000327	0.00168	CcSEcCtD
Iloperidone—Paraesthesia—Mitoxantrone—multiple sclerosis	0.000326	0.00167	CcSEcCtD
Iloperidone—Dyspnoea—Mitoxantrone—multiple sclerosis	0.000324	0.00166	CcSEcCtD
Iloperidone—CYP3A4—nervous system—multiple sclerosis	0.000323	0.00188	CbGeAlD
Iloperidone—Somnolence—Mitoxantrone—multiple sclerosis	0.000323	0.00165	CcSEcCtD
Iloperidone—HRH1—brain—multiple sclerosis	0.00032	0.00186	CbGeAlD
Iloperidone—Asthma—Methotrexate—multiple sclerosis	0.000318	0.00163	CcSEcCtD
Iloperidone—CYP2D6—nervous system—multiple sclerosis	0.000318	0.00185	CbGeAlD
Iloperidone—Angiopathy—Betamethasone—multiple sclerosis	0.000317	0.00163	CcSEcCtD
Iloperidone—Angiopathy—Dexamethasone—multiple sclerosis	0.000317	0.00163	CcSEcCtD
Iloperidone—ADRA2A—brain—multiple sclerosis	0.000314	0.00182	CbGeAlD
Iloperidone—Fatigue—Mitoxantrone—multiple sclerosis	0.000313	0.0016	CcSEcCtD
Iloperidone—Arrhythmia—Dexamethasone—multiple sclerosis	0.000313	0.0016	CcSEcCtD
Iloperidone—Arrhythmia—Betamethasone—multiple sclerosis	0.000313	0.0016	CcSEcCtD
Iloperidone—CYP3A4—central nervous system—multiple sclerosis	0.000311	0.00181	CbGeAlD
Iloperidone—Diarrhoea—Azathioprine—multiple sclerosis	0.000307	0.00157	CcSEcCtD
Iloperidone—CYP2E1—brain—multiple sclerosis	0.000307	0.00178	CbGeAlD
Iloperidone—CYP2D6—central nervous system—multiple sclerosis	0.000306	0.00178	CbGeAlD
Iloperidone—Abdominal discomfort—Methotrexate—multiple sclerosis	0.000305	0.00156	CcSEcCtD
Iloperidone—Vertigo—Triamcinolone—multiple sclerosis	0.000302	0.00155	CcSEcCtD
Iloperidone—Vertigo—Methylprednisolone—multiple sclerosis	0.000301	0.00154	CcSEcCtD
Iloperidone—Connective tissue disorder—Prednisone—multiple sclerosis	0.000299	0.00153	CcSEcCtD
Iloperidone—CYP2D6—cerebellum—multiple sclerosis	0.000299	0.00174	CbGeAlD
Iloperidone—Feeling abnormal—Mitoxantrone—multiple sclerosis	0.000299	0.00153	CcSEcCtD
Iloperidone—Oedema—Prednisolone—multiple sclerosis	0.000298	0.00153	CcSEcCtD
Iloperidone—Dysuria—Methotrexate—multiple sclerosis	0.000297	0.00152	CcSEcCtD
Iloperidone—Dizziness—Azathioprine—multiple sclerosis	0.000297	0.00152	CcSEcCtD
Iloperidone—Upper respiratory tract infection—Methotrexate—multiple sclerosis	0.000296	0.00151	CcSEcCtD
Iloperidone—Erectile dysfunction—Methotrexate—multiple sclerosis	0.000293	0.0015	CcSEcCtD
Iloperidone—Tachycardia—Prednisolone—multiple sclerosis	0.000291	0.00149	CcSEcCtD
Iloperidone—Body temperature increased—Mitoxantrone—multiple sclerosis	0.000287	0.00147	CcSEcCtD
Iloperidone—Myalgia—Triamcinolone—multiple sclerosis	0.000286	0.00146	CcSEcCtD
Iloperidone—Arthralgia—Methylprednisolone—multiple sclerosis	0.000285	0.00146	CcSEcCtD
Iloperidone—Myalgia—Methylprednisolone—multiple sclerosis	0.000285	0.00146	CcSEcCtD
Iloperidone—Eye disorder—Prednisone—multiple sclerosis	0.000285	0.00146	CcSEcCtD
Iloperidone—Rash—Azathioprine—multiple sclerosis	0.000283	0.00145	CcSEcCtD
Iloperidone—Dermatitis—Azathioprine—multiple sclerosis	0.000283	0.00145	CcSEcCtD
Iloperidone—Dry mouth—Triamcinolone—multiple sclerosis	0.000279	0.00143	CcSEcCtD
Iloperidone—Stomatitis—Methotrexate—multiple sclerosis	0.000276	0.00142	CcSEcCtD
Iloperidone—Angiopathy—Prednisone—multiple sclerosis	0.000276	0.00142	CcSEcCtD
Iloperidone—Conjunctivitis—Methotrexate—multiple sclerosis	0.000276	0.00141	CcSEcCtD
Iloperidone—Confusional state—Methylprednisolone—multiple sclerosis	0.000276	0.00141	CcSEcCtD
Iloperidone—Oedema—Triamcinolone—multiple sclerosis	0.000274	0.0014	CcSEcCtD
Iloperidone—Vertigo—Dexamethasone—multiple sclerosis	0.000274	0.0014	CcSEcCtD
Iloperidone—Vertigo—Betamethasone—multiple sclerosis	0.000274	0.0014	CcSEcCtD
Iloperidone—Arrhythmia—Prednisone—multiple sclerosis	0.000272	0.00139	CcSEcCtD
Iloperidone—Infection—Triamcinolone—multiple sclerosis	0.000272	0.00139	CcSEcCtD
Iloperidone—Infection—Methylprednisolone—multiple sclerosis	0.000272	0.00139	CcSEcCtD
Iloperidone—Hepatobiliary disease—Methotrexate—multiple sclerosis	0.000268	0.00137	CcSEcCtD
Iloperidone—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000268	0.00137	CcSEcCtD
Iloperidone—Epistaxis—Methotrexate—multiple sclerosis	0.000268	0.00137	CcSEcCtD
Iloperidone—Paraesthesia—Prednisolone—multiple sclerosis	0.000267	0.00137	CcSEcCtD
Iloperidone—Tachycardia—Triamcinolone—multiple sclerosis	0.000267	0.00137	CcSEcCtD
Iloperidone—Mental disorder—Prednisone—multiple sclerosis	0.000267	0.00137	CcSEcCtD
Iloperidone—HTR2A—brain—multiple sclerosis	0.000267	0.00155	CbGeAlD
Iloperidone—Nausea—Azathioprine—multiple sclerosis	0.000267	0.00137	CcSEcCtD
Iloperidone—Tachycardia—Methylprednisolone—multiple sclerosis	0.000267	0.00137	CcSEcCtD
Iloperidone—Malnutrition—Prednisone—multiple sclerosis	0.000265	0.00136	CcSEcCtD
Iloperidone—Asthenia—Mitoxantrone—multiple sclerosis	0.000261	0.00133	CcSEcCtD
Iloperidone—Myalgia—Dexamethasone—multiple sclerosis	0.000259	0.00133	CcSEcCtD
Iloperidone—Myalgia—Betamethasone—multiple sclerosis	0.000259	0.00133	CcSEcCtD
Iloperidone—Hypotension—Methylprednisolone—multiple sclerosis	0.000255	0.00131	CcSEcCtD
Iloperidone—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000251	0.00129	CcSEcCtD
Iloperidone—Vision blurred—Prednisone—multiple sclerosis	0.00025	0.00128	CcSEcCtD
Iloperidone—Urethral disorder—Methotrexate—multiple sclerosis	0.00025	0.00128	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.00025	0.00128	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000249	0.00128	CcSEcCtD
Iloperidone—Oedema—Betamethasone—multiple sclerosis	0.000249	0.00127	CcSEcCtD
Iloperidone—Oedema—Dexamethasone—multiple sclerosis	0.000249	0.00127	CcSEcCtD
Iloperidone—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000248	0.00127	CcSEcCtD
Iloperidone—Infection—Dexamethasone—multiple sclerosis	0.000247	0.00127	CcSEcCtD
Iloperidone—Infection—Betamethasone—multiple sclerosis	0.000247	0.00127	CcSEcCtD
Iloperidone—Paraesthesia—Triamcinolone—multiple sclerosis	0.000246	0.00126	CcSEcCtD
Iloperidone—Feeling abnormal—Prednisolone—multiple sclerosis	0.000245	0.00126	CcSEcCtD
Iloperidone—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000245	0.00126	CcSEcCtD
Iloperidone—Anaemia—Prednisone—multiple sclerosis	0.000245	0.00126	CcSEcCtD
Iloperidone—Dyspnoea—Triamcinolone—multiple sclerosis	0.000244	0.00125	CcSEcCtD
Iloperidone—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000244	0.00125	CcSEcCtD
Iloperidone—Nervous system disorder—Betamethasone—multiple sclerosis	0.000244	0.00125	CcSEcCtD
Iloperidone—Agitation—Prednisone—multiple sclerosis	0.000244	0.00125	CcSEcCtD
Iloperidone—CYP2D6—brain—multiple sclerosis	0.000243	0.00141	CbGeAlD
Iloperidone—Tachycardia—Dexamethasone—multiple sclerosis	0.000243	0.00124	CcSEcCtD
Iloperidone—Tachycardia—Betamethasone—multiple sclerosis	0.000243	0.00124	CcSEcCtD
Iloperidone—Vertigo—Prednisone—multiple sclerosis	0.000238	0.00122	CcSEcCtD
Iloperidone—Eye disorder—Methotrexate—multiple sclerosis	0.000238	0.00122	CcSEcCtD
Iloperidone—Tinnitus—Methotrexate—multiple sclerosis	0.000237	0.00122	CcSEcCtD
Iloperidone—Cardiac disorder—Methotrexate—multiple sclerosis	0.000236	0.00121	CcSEcCtD
Iloperidone—Fatigue—Triamcinolone—multiple sclerosis	0.000236	0.00121	CcSEcCtD
Iloperidone—Fatigue—Methylprednisolone—multiple sclerosis	0.000236	0.00121	CcSEcCtD
Iloperidone—Hypotension—Betamethasone—multiple sclerosis	0.000232	0.00119	CcSEcCtD
Iloperidone—Hypotension—Dexamethasone—multiple sclerosis	0.000232	0.00119	CcSEcCtD
Iloperidone—Angiopathy—Methotrexate—multiple sclerosis	0.000231	0.00118	CcSEcCtD
Iloperidone—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000229	0.00118	CcSEcCtD
Iloperidone—Rash—Mitoxantrone—multiple sclerosis	0.000229	0.00117	CcSEcCtD
Iloperidone—Dermatitis—Mitoxantrone—multiple sclerosis	0.000229	0.00117	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000226	0.00116	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000226	0.00116	CcSEcCtD
Iloperidone—Arthralgia—Prednisone—multiple sclerosis	0.000226	0.00116	CcSEcCtD
Iloperidone—Myalgia—Prednisone—multiple sclerosis	0.000226	0.00116	CcSEcCtD
Iloperidone—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000226	0.00116	CcSEcCtD
Iloperidone—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000225	0.00115	CcSEcCtD
Iloperidone—Paraesthesia—Betamethasone—multiple sclerosis	0.000223	0.00114	CcSEcCtD
Iloperidone—Paraesthesia—Dexamethasone—multiple sclerosis	0.000223	0.00114	CcSEcCtD
Iloperidone—Mental disorder—Methotrexate—multiple sclerosis	0.000223	0.00114	CcSEcCtD
Iloperidone—Malnutrition—Methotrexate—multiple sclerosis	0.000222	0.00114	CcSEcCtD
Iloperidone—Body temperature increased—Triamcinolone—multiple sclerosis	0.000217	0.00111	CcSEcCtD
Iloperidone—Oedema—Prednisone—multiple sclerosis	0.000216	0.00111	CcSEcCtD
Iloperidone—Nausea—Mitoxantrone—multiple sclerosis	0.000216	0.0011	CcSEcCtD
Iloperidone—Infection—Prednisone—multiple sclerosis	0.000215	0.0011	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000215	0.0011	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000215	0.0011	CcSEcCtD
Iloperidone—Fatigue—Dexamethasone—multiple sclerosis	0.000214	0.0011	CcSEcCtD
Iloperidone—Fatigue—Betamethasone—multiple sclerosis	0.000214	0.0011	CcSEcCtD
Iloperidone—Nervous system disorder—Prednisone—multiple sclerosis	0.000212	0.00109	CcSEcCtD
Iloperidone—Tachycardia—Prednisone—multiple sclerosis	0.000211	0.00108	CcSEcCtD
Iloperidone—Vision blurred—Methotrexate—multiple sclerosis	0.000209	0.00107	CcSEcCtD
Iloperidone—Anaemia—Methotrexate—multiple sclerosis	0.000205	0.00105	CcSEcCtD
Iloperidone—Feeling abnormal—Dexamethasone—multiple sclerosis	0.000205	0.00105	CcSEcCtD
Iloperidone—Feeling abnormal—Betamethasone—multiple sclerosis	0.000205	0.00105	CcSEcCtD
Iloperidone—Vertigo—Methotrexate—multiple sclerosis	0.000199	0.00102	CcSEcCtD
Iloperidone—Leukopenia—Methotrexate—multiple sclerosis	0.000198	0.00102	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000197	0.00101	CcSEcCtD
Iloperidone—Dizziness—Prednisolone—multiple sclerosis	0.000197	0.00101	CcSEcCtD
Iloperidone—Asthenia—Triamcinolone—multiple sclerosis	0.000197	0.00101	CcSEcCtD
Iloperidone—Body temperature increased—Betamethasone—multiple sclerosis	0.000197	0.00101	CcSEcCtD
Iloperidone—Body temperature increased—Dexamethasone—multiple sclerosis	0.000197	0.00101	CcSEcCtD
Iloperidone—Asthenia—Methylprednisolone—multiple sclerosis	0.000196	0.001	CcSEcCtD
Iloperidone—Paraesthesia—Prednisone—multiple sclerosis	0.000194	0.000996	CcSEcCtD
Iloperidone—Myalgia—Methotrexate—multiple sclerosis	0.000189	0.000967	CcSEcCtD
Iloperidone—Arthralgia—Methotrexate—multiple sclerosis	0.000189	0.000967	CcSEcCtD
Iloperidone—Rash—Prednisolone—multiple sclerosis	0.000188	0.000962	CcSEcCtD
Iloperidone—Dermatitis—Prednisolone—multiple sclerosis	0.000188	0.000961	CcSEcCtD
Iloperidone—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000187	0.000958	CcSEcCtD
Iloperidone—Fatigue—Prednisone—multiple sclerosis	0.000187	0.000956	CcSEcCtD
Iloperidone—Confusional state—Methotrexate—multiple sclerosis	0.000182	0.000935	CcSEcCtD
Iloperidone—Dizziness—Triamcinolone—multiple sclerosis	0.000181	0.000928	CcSEcCtD
Iloperidone—Dizziness—Methylprednisolone—multiple sclerosis	0.000181	0.000926	CcSEcCtD
Iloperidone—Infection—Methotrexate—multiple sclerosis	0.00018	0.000921	CcSEcCtD
Iloperidone—Feeling abnormal—Prednisone—multiple sclerosis	0.000178	0.000914	CcSEcCtD
Iloperidone—Asthenia—Dexamethasone—multiple sclerosis	0.000178	0.000914	CcSEcCtD
Iloperidone—Asthenia—Betamethasone—multiple sclerosis	0.000178	0.000914	CcSEcCtD
Iloperidone—Nervous system disorder—Methotrexate—multiple sclerosis	0.000177	0.000909	CcSEcCtD
Iloperidone—Nausea—Prednisolone—multiple sclerosis	0.000177	0.000907	CcSEcCtD
Iloperidone—Rash—Triamcinolone—multiple sclerosis	0.000173	0.000885	CcSEcCtD
Iloperidone—Dermatitis—Triamcinolone—multiple sclerosis	0.000173	0.000884	CcSEcCtD
Iloperidone—Rash—Methylprednisolone—multiple sclerosis	0.000172	0.000883	CcSEcCtD
Iloperidone—Dermatitis—Methylprednisolone—multiple sclerosis	0.000172	0.000882	CcSEcCtD
Iloperidone—Body temperature increased—Prednisone—multiple sclerosis	0.000171	0.000877	CcSEcCtD
Iloperidone—Diarrhoea—Dexamethasone—multiple sclerosis	0.00017	0.000871	CcSEcCtD
Iloperidone—Diarrhoea—Betamethasone—multiple sclerosis	0.00017	0.000871	CcSEcCtD
Iloperidone—Hypotension—Methotrexate—multiple sclerosis	0.000169	0.000866	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000165	0.000844	CcSEcCtD
Iloperidone—Dizziness—Betamethasone—multiple sclerosis	0.000164	0.000842	CcSEcCtD
Iloperidone—Dizziness—Dexamethasone—multiple sclerosis	0.000164	0.000842	CcSEcCtD
Iloperidone—Nausea—Triamcinolone—multiple sclerosis	0.000163	0.000834	CcSEcCtD
Iloperidone—Paraesthesia—Methotrexate—multiple sclerosis	0.000162	0.000832	CcSEcCtD
Iloperidone—Nausea—Methylprednisolone—multiple sclerosis	0.000162	0.000832	CcSEcCtD
Iloperidone—Dyspnoea—Methotrexate—multiple sclerosis	0.000161	0.000826	CcSEcCtD
Iloperidone—Somnolence—Methotrexate—multiple sclerosis	0.000161	0.000824	CcSEcCtD
Iloperidone—Rash—Betamethasone—multiple sclerosis	0.000157	0.000803	CcSEcCtD
Iloperidone—Rash—Dexamethasone—multiple sclerosis	0.000157	0.000803	CcSEcCtD
Iloperidone—Dermatitis—Betamethasone—multiple sclerosis	0.000157	0.000802	CcSEcCtD
Iloperidone—Dermatitis—Dexamethasone—multiple sclerosis	0.000157	0.000802	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000156	0.0008	CcSEcCtD
Iloperidone—Fatigue—Methotrexate—multiple sclerosis	0.000156	0.000799	CcSEcCtD
Iloperidone—Asthenia—Prednisone—multiple sclerosis	0.000155	0.000796	CcSEcCtD
Iloperidone—Feeling abnormal—Methotrexate—multiple sclerosis	0.000149	0.000764	CcSEcCtD
Iloperidone—Diarrhoea—Prednisone—multiple sclerosis	0.000148	0.000759	CcSEcCtD
Iloperidone—Nausea—Dexamethasone—multiple sclerosis	0.000148	0.000756	CcSEcCtD
Iloperidone—Nausea—Betamethasone—multiple sclerosis	0.000148	0.000756	CcSEcCtD
Iloperidone—Dizziness—Prednisone—multiple sclerosis	0.000143	0.000733	CcSEcCtD
Iloperidone—Body temperature increased—Methotrexate—multiple sclerosis	0.000143	0.000733	CcSEcCtD
Iloperidone—Rash—Prednisone—multiple sclerosis	0.000136	0.000699	CcSEcCtD
Iloperidone—Dermatitis—Prednisone—multiple sclerosis	0.000136	0.000699	CcSEcCtD
Iloperidone—Asthenia—Methotrexate—multiple sclerosis	0.00013	0.000665	CcSEcCtD
Iloperidone—Nausea—Prednisone—multiple sclerosis	0.000129	0.000659	CcSEcCtD
Iloperidone—Diarrhoea—Methotrexate—multiple sclerosis	0.000124	0.000634	CcSEcCtD
Iloperidone—Dizziness—Methotrexate—multiple sclerosis	0.00012	0.000613	CcSEcCtD
Iloperidone—Rash—Methotrexate—multiple sclerosis	0.000114	0.000584	CcSEcCtD
Iloperidone—Dermatitis—Methotrexate—multiple sclerosis	0.000114	0.000584	CcSEcCtD
Iloperidone—Nausea—Methotrexate—multiple sclerosis	0.000107	0.000551	CcSEcCtD
Iloperidone—HTR1A—Signaling Pathways—CCR5—multiple sclerosis	1.36e-05	9.75e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—CCR5—multiple sclerosis	1.35e-05	9.7e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—SPP1—multiple sclerosis	1.35e-05	9.69e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling by GPCR—TYK2—multiple sclerosis	1.35e-05	9.69e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—CD86—multiple sclerosis	1.34e-05	9.65e-05	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—CCL2—multiple sclerosis	1.34e-05	9.63e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—IL2RA—multiple sclerosis	1.34e-05	9.6e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—IL2RA—multiple sclerosis	1.33e-05	9.56e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling by GPCR—IL2—multiple sclerosis	1.33e-05	9.53e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—CCL5—multiple sclerosis	1.32e-05	9.5e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—CD86—multiple sclerosis	1.32e-05	9.49e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling by GPCR—IL2—multiple sclerosis	1.32e-05	9.48e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—CD86—multiple sclerosis	1.32e-05	9.47e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—CCR5—multiple sclerosis	1.31e-05	9.43e-05	CbGpPWpGaD
Iloperidone—DRD4—Signaling by GPCR—MAPK1—multiple sclerosis	1.31e-05	9.42e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—CCL5—multiple sclerosis	1.3e-05	9.35e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—CCL5—multiple sclerosis	1.3e-05	9.33e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—CD80—multiple sclerosis	1.3e-05	9.32e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—CD86—multiple sclerosis	1.29e-05	9.3e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—IL2RA—multiple sclerosis	1.29e-05	9.29e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling by GPCR—IL2—multiple sclerosis	1.28e-05	9.22e-05	CbGpPWpGaD
Iloperidone—DRD2—GPCR downstream signaling—IL2—multiple sclerosis	1.28e-05	9.22e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—CD80—multiple sclerosis	1.28e-05	9.2e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—CCL5—multiple sclerosis	1.27e-05	9.15e-05	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—TYK2—multiple sclerosis	1.27e-05	9.14e-05	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—TYK2—multiple sclerosis	1.27e-05	9.13e-05	CbGpPWpGaD
Iloperidone—CYP3A7—Metabolism—POMC—multiple sclerosis	1.26e-05	9.08e-05	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—TYK2—multiple sclerosis	1.26e-05	9.07e-05	CbGpPWpGaD
Iloperidone—HTR2A—GPCR downstream signaling—IL2—multiple sclerosis	1.26e-05	9.07e-05	CbGpPWpGaD
Iloperidone—HRH1—GPCR downstream signaling—IL2—multiple sclerosis	1.26e-05	9.05e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—BCHE—multiple sclerosis	1.26e-05	9.03e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling by GPCR—TYK2—multiple sclerosis	1.25e-05	9e-05	CbGpPWpGaD
Iloperidone—ADRA1A—GPCR downstream signaling—IL2—multiple sclerosis	1.24e-05	8.88e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.24e-05	8.87e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—APOE—multiple sclerosis	1.23e-05	8.87e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—POMC—multiple sclerosis	1.23e-05	8.86e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—APOE—multiple sclerosis	1.23e-05	8.82e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Metabolism—POMC—multiple sclerosis	1.23e-05	8.81e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—SPP1—multiple sclerosis	1.22e-05	8.8e-05	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—TYK2—multiple sclerosis	1.22e-05	8.74e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—POMC—multiple sclerosis	1.22e-05	8.74e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—CCL2—multiple sclerosis	1.21e-05	8.67e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—SPP1—multiple sclerosis	1.2e-05	8.65e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—CD86—multiple sclerosis	1.2e-05	8.64e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—SPP1—multiple sclerosis	1.2e-05	8.64e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—APOE—multiple sclerosis	1.19e-05	8.58e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—CCR5—multiple sclerosis	1.19e-05	8.56e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—CCL2—multiple sclerosis	1.19e-05	8.55e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—CCL5—multiple sclerosis	1.18e-05	8.5e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling by GPCR—MAPK1—multiple sclerosis	1.18e-05	8.48e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—SPP1—multiple sclerosis	1.18e-05	8.47e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—IL2RA—multiple sclerosis	1.17e-05	8.43e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—CCR5—multiple sclerosis	1.17e-05	8.42e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—CCR5—multiple sclerosis	1.17e-05	8.4e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling by GPCR—IL2—multiple sclerosis	1.16e-05	8.37e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling by GPCR—MAPK1—multiple sclerosis	1.16e-05	8.37e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Metabolism—APOE—multiple sclerosis	1.16e-05	8.33e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—IL2RA—multiple sclerosis	1.15e-05	8.3e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—IL2RA—multiple sclerosis	1.15e-05	8.28e-05	CbGpPWpGaD
Iloperidone—CYP3A7—Metabolism—ALB—multiple sclerosis	1.15e-05	8.27e-05	CbGpPWpGaD
Iloperidone—ADRA2A—GPCR downstream signaling—IL2—multiple sclerosis	1.15e-05	8.25e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—CCR5—multiple sclerosis	1.15e-05	8.24e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling by GPCR—IL2—multiple sclerosis	1.15e-05	8.23e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling by GPCR—IL2—multiple sclerosis	1.14e-05	8.22e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—IL2RA—multiple sclerosis	1.13e-05	8.12e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.13e-05	8.09e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling by GPCR—IL2—multiple sclerosis	1.12e-05	8.06e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Metabolism—ALB—multiple sclerosis	1.12e-05	8.04e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—CD80—multiple sclerosis	1.12e-05	8.02e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—CD80—multiple sclerosis	1.11e-05	7.98e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—SPP1—multiple sclerosis	1.1e-05	7.87e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—TYK2—multiple sclerosis	1.1e-05	7.87e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—APOE—multiple sclerosis	1.08e-05	7.78e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—TYK2—multiple sclerosis	1.08e-05	7.76e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—CD80—multiple sclerosis	1.08e-05	7.76e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—CCR5—multiple sclerosis	1.07e-05	7.66e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—APOE—multiple sclerosis	1.07e-05	7.66e-05	CbGpPWpGaD
Iloperidone—CYP2E1—Metabolism—APOE—multiple sclerosis	1.07e-05	7.65e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—BCHE—multiple sclerosis	1.06e-05	7.65e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—APOE—multiple sclerosis	1.06e-05	7.64e-05	CbGpPWpGaD
Iloperidone—CYP3A5—Metabolism—APOE—multiple sclerosis	1.06e-05	7.64e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—POMC—multiple sclerosis	1.06e-05	7.62e-05	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—IL2—multiple sclerosis	1.06e-05	7.61e-05	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—IL2—multiple sclerosis	1.06e-05	7.6e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—POMC—multiple sclerosis	1.05e-05	7.58e-05	CbGpPWpGaD
Iloperidone—HTR6—Signaling by GPCR—IL6—multiple sclerosis	1.05e-05	7.57e-05	CbGpPWpGaD
Iloperidone—HTR7—Signaling by GPCR—IL6—multiple sclerosis	1.05e-05	7.56e-05	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—IL2—multiple sclerosis	1.05e-05	7.55e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—IL2RA—multiple sclerosis	1.05e-05	7.55e-05	CbGpPWpGaD
Iloperidone—HTR1D—Signaling by GPCR—IL6—multiple sclerosis	1.05e-05	7.51e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—APOE—multiple sclerosis	1.04e-05	7.5e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling by GPCR—IL2—multiple sclerosis	1.04e-05	7.49e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—CCL2—multiple sclerosis	1.04e-05	7.45e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—CCL2—multiple sclerosis	1.03e-05	7.41e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—POMC—multiple sclerosis	1.03e-05	7.37e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling by GPCR—MAPK1—multiple sclerosis	1.01e-05	7.29e-05	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—IL2—multiple sclerosis	1.01e-05	7.27e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling by GPCR—MAPK1—multiple sclerosis	1.01e-05	7.25e-05	CbGpPWpGaD
Iloperidone—DRD4—Signaling by GPCR—IL6—multiple sclerosis	1.01e-05	7.24e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—CCL2—multiple sclerosis	1e-05	7.21e-05	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—MMP9—multiple sclerosis	1e-05	7.2e-05	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—MMP9—multiple sclerosis	1e-05	7.19e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Metabolism—POMC—multiple sclerosis	9.97e-06	7.16e-05	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—MMP9—multiple sclerosis	9.94e-06	7.14e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling by GPCR—MAPK1—multiple sclerosis	9.82e-06	7.06e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—CD80—multiple sclerosis	9.8e-06	7.04e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—APOE—multiple sclerosis	9.7e-06	6.97e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—CD80—multiple sclerosis	9.64e-06	6.93e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—CD80—multiple sclerosis	9.62e-06	6.91e-05	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—MMP9—multiple sclerosis	9.58e-06	6.88e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—CD80—multiple sclerosis	9.44e-06	6.78e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—TYK2—multiple sclerosis	9.42e-06	6.77e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—TYK2—multiple sclerosis	9.37e-06	6.73e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—POMC—multiple sclerosis	9.31e-06	6.69e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—POMC—multiple sclerosis	9.16e-06	6.58e-05	CbGpPWpGaD
Iloperidone—CYP2E1—Metabolism—POMC—multiple sclerosis	9.15e-06	6.57e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—POMC—multiple sclerosis	9.14e-06	6.57e-05	CbGpPWpGaD
Iloperidone—CYP3A5—Metabolism—POMC—multiple sclerosis	9.13e-06	6.56e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—TYK2—multiple sclerosis	9.11e-06	6.55e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—IL2—multiple sclerosis	9.11e-06	6.55e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—CCL2—multiple sclerosis	9.11e-06	6.54e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Metabolism—ALB—multiple sclerosis	9.09e-06	6.53e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling by GPCR—IL6—multiple sclerosis	9.07e-06	6.52e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—IL2—multiple sclerosis	8.99e-06	6.46e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—POMC—multiple sclerosis	8.97e-06	6.44e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—CCL2—multiple sclerosis	8.96e-06	6.44e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling by GPCR—IL6—multiple sclerosis	8.95e-06	6.43e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—CCL2—multiple sclerosis	8.94e-06	6.42e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling by GPCR—MAPK1—multiple sclerosis	8.91e-06	6.4e-05	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—STAT3—multiple sclerosis	8.91e-06	6.4e-05	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—STAT3—multiple sclerosis	8.9e-06	6.39e-05	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—STAT3—multiple sclerosis	8.84e-06	6.35e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—CCL2—multiple sclerosis	8.77e-06	6.3e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—CD80—multiple sclerosis	8.77e-06	6.3e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling by GPCR—MAPK1—multiple sclerosis	8.77e-06	6.3e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling by GPCR—MAPK1—multiple sclerosis	8.75e-06	6.29e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—MMP9—multiple sclerosis	8.63e-06	6.2e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling by GPCR—MAPK1—multiple sclerosis	8.59e-06	6.17e-05	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—STAT3—multiple sclerosis	8.52e-06	6.12e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—MMP9—multiple sclerosis	8.51e-06	6.11e-05	CbGpPWpGaD
Iloperidone—CYP2E1—Metabolism—ALB—multiple sclerosis	8.34e-06	5.99e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—POMC—multiple sclerosis	8.33e-06	5.99e-05	CbGpPWpGaD
Iloperidone—CYP3A5—Metabolism—ALB—multiple sclerosis	8.33e-06	5.98e-05	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—MYC—multiple sclerosis	8.28e-06	5.95e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—TYK2—multiple sclerosis	8.27e-06	5.94e-05	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—MYC—multiple sclerosis	8.27e-06	5.94e-05	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—TGFB1—multiple sclerosis	8.26e-06	5.93e-05	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—TGFB1—multiple sclerosis	8.25e-06	5.93e-05	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—MYC—multiple sclerosis	8.22e-06	5.9e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—BCHE—multiple sclerosis	8.22e-06	5.9e-05	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—TGFB1—multiple sclerosis	8.2e-06	5.89e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—CCL2—multiple sclerosis	8.15e-06	5.86e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—TYK2—multiple sclerosis	8.14e-06	5.85e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—TYK2—multiple sclerosis	8.12e-06	5.83e-05	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—MAPK1—multiple sclerosis	8.1e-06	5.82e-05	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—MAPK1—multiple sclerosis	8.09e-06	5.81e-05	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—MAPK1—multiple sclerosis	8.04e-06	5.77e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling by GPCR—MAPK1—multiple sclerosis	7.98e-06	5.73e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—TYK2—multiple sclerosis	7.97e-06	5.72e-05	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—MYC—multiple sclerosis	7.92e-06	5.69e-05	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—TGFB1—multiple sclerosis	7.9e-06	5.67e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—IL2—multiple sclerosis	7.84e-06	5.63e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling by GPCR—IL6—multiple sclerosis	7.8e-06	5.6e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—IL2—multiple sclerosis	7.8e-06	5.6e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling by GPCR—IL6—multiple sclerosis	7.76e-06	5.57e-05	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—MAPK1—multiple sclerosis	7.74e-06	5.56e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—STAT3—multiple sclerosis	7.67e-06	5.51e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—IL2—multiple sclerosis	7.58e-06	5.45e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—STAT3—multiple sclerosis	7.57e-06	5.44e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—APOE—multiple sclerosis	7.56e-06	5.43e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling by GPCR—IL6—multiple sclerosis	7.55e-06	5.42e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—MMP9—multiple sclerosis	7.42e-06	5.33e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—TYK2—multiple sclerosis	7.4e-06	5.32e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—MMP9—multiple sclerosis	7.38e-06	5.3e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—MMP9—multiple sclerosis	7.18e-06	5.16e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—MYC—multiple sclerosis	7.13e-06	5.12e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—TGFB1—multiple sclerosis	7.11e-06	5.11e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—MYC—multiple sclerosis	7.03e-06	5.05e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—TGFB1—multiple sclerosis	7.01e-06	5.04e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—MAPK1—multiple sclerosis	6.97e-06	5.01e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—IL2—multiple sclerosis	6.88e-06	4.94e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—MAPK1—multiple sclerosis	6.88e-06	4.94e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling by GPCR—IL6—multiple sclerosis	6.85e-06	4.92e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—IL2—multiple sclerosis	6.77e-06	4.86e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—IL2—multiple sclerosis	6.76e-06	4.85e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling by GPCR—IL6—multiple sclerosis	6.74e-06	4.84e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling by GPCR—IL6—multiple sclerosis	6.72e-06	4.83e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—IL2—multiple sclerosis	6.63e-06	4.76e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling by GPCR—IL6—multiple sclerosis	6.6e-06	4.74e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—STAT3—multiple sclerosis	6.6e-06	4.74e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—STAT3—multiple sclerosis	6.56e-06	4.71e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—MMP9—multiple sclerosis	6.51e-06	4.68e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—POMC—multiple sclerosis	6.49e-06	4.67e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—MMP9—multiple sclerosis	6.41e-06	4.6e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—APOE—multiple sclerosis	6.4e-06	4.6e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—MMP9—multiple sclerosis	6.39e-06	4.59e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—STAT3—multiple sclerosis	6.38e-06	4.59e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—MMP9—multiple sclerosis	6.27e-06	4.51e-05	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—IL6—multiple sclerosis	6.22e-06	4.47e-05	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—IL6—multiple sclerosis	6.22e-06	4.47e-05	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—IL6—multiple sclerosis	6.18e-06	4.44e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—IL2—multiple sclerosis	6.16e-06	4.43e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling by GPCR—IL6—multiple sclerosis	6.13e-06	4.4e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—MYC—multiple sclerosis	6.13e-06	4.4e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—TGFB1—multiple sclerosis	6.11e-06	4.39e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—MYC—multiple sclerosis	6.1e-06	4.38e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—TGFB1—multiple sclerosis	6.08e-06	4.37e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—MAPK1—multiple sclerosis	6e-06	4.31e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—MAPK1—multiple sclerosis	5.96e-06	4.29e-05	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—IL6—multiple sclerosis	5.95e-06	4.28e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—MYC—multiple sclerosis	5.93e-06	4.26e-05	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—ALB—multiple sclerosis	5.92e-06	4.25e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—TGFB1—multiple sclerosis	5.92e-06	4.25e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—MMP9—multiple sclerosis	5.83e-06	4.19e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—MAPK1—multiple sclerosis	5.8e-06	4.17e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—STAT3—multiple sclerosis	5.79e-06	4.16e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—STAT3—multiple sclerosis	5.7e-06	4.09e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—STAT3—multiple sclerosis	5.69e-06	4.08e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—STAT3—multiple sclerosis	5.58e-06	4.01e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—POMC—multiple sclerosis	5.5e-06	3.95e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—MYC—multiple sclerosis	5.38e-06	3.87e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—TGFB1—multiple sclerosis	5.37e-06	3.86e-05	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—IL6—multiple sclerosis	5.36e-06	3.85e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—MYC—multiple sclerosis	5.29e-06	3.8e-05	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—IL6—multiple sclerosis	5.29e-06	3.8e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—MYC—multiple sclerosis	5.28e-06	3.8e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—TGFB1—multiple sclerosis	5.28e-06	3.79e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—TGFB1—multiple sclerosis	5.27e-06	3.79e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—MAPK1—multiple sclerosis	5.26e-06	3.78e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—MYC—multiple sclerosis	5.18e-06	3.72e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—STAT3—multiple sclerosis	5.18e-06	3.72e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—MAPK1—multiple sclerosis	5.18e-06	3.72e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—TGFB1—multiple sclerosis	5.17e-06	3.72e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—MAPK1—multiple sclerosis	5.17e-06	3.71e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—MAPK1—multiple sclerosis	5.07e-06	3.64e-05	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—ALB—multiple sclerosis	5.02e-06	3.6e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—APOE—multiple sclerosis	4.94e-06	3.55e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—MYC—multiple sclerosis	4.82e-06	3.46e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—TGFB1—multiple sclerosis	4.81e-06	3.45e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—MAPK1—multiple sclerosis	4.71e-06	3.39e-05	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—IL6—multiple sclerosis	4.61e-06	3.31e-05	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—IL6—multiple sclerosis	4.58e-06	3.29e-05	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—IL6—multiple sclerosis	4.46e-06	3.2e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—POMC—multiple sclerosis	4.25e-06	3.05e-05	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—IL6—multiple sclerosis	4.04e-06	2.91e-05	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—IL6—multiple sclerosis	3.98e-06	2.86e-05	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—IL6—multiple sclerosis	3.97e-06	2.85e-05	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—IL6—multiple sclerosis	3.9e-06	2.8e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—ALB—multiple sclerosis	3.87e-06	2.78e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—IL6—multiple sclerosis	3.62e-06	2.6e-05	CbGpPWpGaD
